The safety and efficacy of CTLA-4 blockade with ipilimumab has been evaluated in a number of phase I, II, and III trials demonstrating that therapy with ipilimumab may result in a significant improvement in OS for a selected group of patients with metastatic melanoma. Here, CTLA4 is linked to metastatic melanoma.